Fiche centre
Research Site
Cologne — Germany
Essais liés7clinical trials
VilleColognelocalisation
PaysGermanylocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT00252863
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Symbicort, used twice daily (b.i.d) and as needed (prn) | SEP | Phase 3 | NCT00252863 | DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults | COMPLETED |
| ASTER — A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice | Lupus | À vérifier | NCT05637112 | ASTER — A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice | ACTIVE_NOT_RECRUITING |
| AZD5492 | Lupus | Phase 1 | NCT06916806 | TITAN — A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | RECRUITING |
| Rilvegostomig | Cancer | Phase 3 | NCT06627647 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | RECRUITING |
| Medi-546 | Lupus | Phase 3 | NCT04877691 | Tulip SC — Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| Anifrolumab | Lupus | Phase 3 | NCT05138133 | IRIS — Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| Rilvegostomig | Cancer | Phase 3 | NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | RECRUITING |